GBS Inc. Reports Third Quarter 2022 Financial Results and Re

- Initiated prospective study to collect coincident samples of oral fluidand blood following IRB approval -

Related Keywords

United States , American , Alex Arzeno , Tim Mccarthy , Steven Boyages , Linkedin , Lifesci Advisors , Ir Communications Gbs Inc , Twitter , Nasdaq , Gbs Inc , Exchange Commission , Biosensor Algorithm Development , Department Of Pathology , Securities Exchange , Quest Diagnostics , University Of Newcastle , Clinical Development Initiated Trial , Cash Equivalents , Marketable Securities , Institutional Review Board , Chief Executive Officer , Johns Hopkins Hospital , Development Initiated Trial , Specimen Collection Methodology , Support Subsequent Correlation , Oral Fluids , Algorithm Development , North American , Webcast Registration , Biosensor Platform , Forward Looking Statements , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Vice President , Managing Director Lifesci Advisors , Money , Ational ,